Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Of India Markets Generic of Bayer's Kidney Cancer Drug

This article was originally published in PharmAsia News

Executive Summary

India's Cipla has launched at home a generic version of Nexavar (sorafenib) marketed by Germany's Bayer to treat kidney cancer

You may also be interested in...



Sharing "Schering" Link Gets Bayer And Cadila To Talk Joint Venture; Deal Spanning Market To Manufacturing Likely In Final Stages

MUMBAI - Germany-headquartered agrichemicals-to-healthcare behemoth Bayer is talking to India's Cadila Healthcare to form an equal stake joint venture that will revolve around selling its own branded and generic products as well as contracting out a significant part of its manufacturing requirements

Novartis Q4 Preview: Launches Likely To Deliver

Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.

Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot

Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.

UsernamePublicRestriction

Register

SC074747

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel